A STAT Plus analysis reports that U.S. health spending experienced a significant increase in 2025, driven largely by the utilization of GLP-1 medications and a general rise in the demand for healthcare services. The report identifies the widespread adoption of these weight-loss and diabetes drugs as a primary factor behind the sharp financial escalation.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.